TD.NYSEToronto Dominion Bank

SCHEDULE: TD Bank Discloses 5.8% Stake in Stoke Therapeutics

Sentiment:

Beneficial Ownership Report

📋All filings for Toronto Dominion Bank
🔒Login to Follow

The Toronto-Dominion Bank has reported a 5.8% beneficial ownership stake in Stoke Therapeutics, Inc., holding 3,173,258 shares of common stock.

Summary

  • The Toronto-Dominion Bank (TD Bank) has filed a Schedule 13G, reporting beneficial ownership of 3,173,258 shares of common stock in Stoke Therapeutics, Inc.
  • This stake represents 5.8% of Stoke Therapeutics' common stock.
  • TD Bank holds sole voting power and sole dispositive power over all 3,173,258 shares.
  • The event requiring this filing, where TD Bank crossed the 5% ownership threshold, occurred on September 30, 2025.
  • The beneficial ownership of these securities was transferred to The Toronto-Dominion Bank from Cowen Financial Products LLC, an affiliated entity, between the event date and the filing date.

Sentiment

Score: 6

Explanation: The filing reports a significant beneficial ownership stake by a major financial institution, which can be viewed as a positive signal of confidence in the issuer. However, it contains no operational or financial performance details.

Positives

  • A major financial institution like The Toronto-Dominion Bank acquiring a significant stake (5.8%) could be interpreted as a vote of confidence in Stoke Therapeutics, Inc.'s long-term prospects.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment by a major bank in a biotechnology company. Such investments can signal confidence in the company's long-term prospects within the competitive biotech sector, which often relies on substantial capital and investor backing for research and development.

Related Party Transactions

  • Beneficial ownership of the securities was transferred from Cowen Financial Products LLC, an affiliated entity, to The Toronto-Dominion Bank between the event date and the filing date.

Stakeholder Impact

  • Shareholders may view the significant stake by a major bank as a positive indicator of institutional confidence, potentially leading to increased investor interest.
  • Management may experience increased scrutiny or engagement from a large institutional investor, though the filing states the shares were not acquired for the purpose of changing or influencing control.

Key Dates

DateDescription
09/30/2025Date of event which required the filing of this statement, indicating when The Toronto-Dominion Bank crossed the 5% beneficial ownership threshold.
11/13/2025Date the Schedule 13G statement was signed by The Toronto-Dominion Bank.

Keywords

Stoke Therapeutics, Toronto-Dominion Bank, TD Bank, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Institutional Investor

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.